A drug that helps promote gene expression reduces repetitive behaviors and improves memory and sociability in a mouse model of autism.
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
Preliminary results suggested the treatment is no better than placebo at reducing the severity of core autism traits.
Experts question data showing that an experimental therapy that parents deliver to babies with early signs of autism can lessen the intensity of the children’s traits and lower their chances of diagnosis at age 3.
Hundreds of preschool-aged children in Kentucky began taking antipsychotic medicines in 2012, according to an analysis of Medicaid records. Lohr discusses what it will it take to get them behavioral therapies instead.
Some types of restricted and repetitive behaviors become more prevalent among autistic children and teenagers over time, depending on their age and intellectual ability, whereas others decrease.
For 40 years, the preponderance of autism research has focused on understanding the causes and characteristics of the condition rather than testing assessments or interventions in community settings.
On 28 September, Jeremy Veenstra-VanderWeele, professor of psychiatry at Columbia University, spoke about goals for developing new drugs for autism — and the barriers researchers may encounter.
The finding that MDMA and an experimental serotonin agonist increase sociability across six different model mice suggests that disparate autism-linked mutations converge on the same underlying pathways.